Denosumab, a human monoclonal antibody that inhibits bone resorption, promotes new bone formation and delays tumor progression by binding to the receptor activator of nuclear factor-ĸB ligand (RANKL) and preventing its interaction with RANK, thus mimicking the action of osteoprotegerin (OPG) (18). Here, TNFRSF11B is linked to neoplasm.